Citations (88)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
R. E. Nappi, L. Tiranini, E. Martini, D. Bosoni, C. Cassani & L. Cucinella. (2023) Different local estrogen therapies for a tailored approach to GSM. Climacteric 26:4, pages 361-366.
Read now
Read now
P. Cox & N. Panay. (2019) Vulvovaginal atrophy in women after cancer. Climacteric 22:6, pages 565-571.
Read now
Read now
D. J. Portman, S. R. Goldstein & R. Kagan. (2019) Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review. Climacteric 22:1, pages 65-72.
Read now
Read now
Ginger D. Constantine, James A. Simon, James H. Pickar, David F. Archer, Brian Bernick, Shelli Graham & Sebastian Mirkin. (2018) Estradiol vaginal inserts (4 µg and 10 µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. Current Medical Research and Opinion 34:12, pages 2131-2136.
Read now
Read now
G. P. Siliquini, V. Tuninetti, V. E. Bounous, F. Bert & N. Biglia. (2017) Fractional CO2 laser therapy: a new challenge for vulvovaginal atrophy in postmenopausal women. Climacteric 20:4, pages 379-384.
Read now
Read now
Santiago Palacios & María Jesús Cancelo. (2016) Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. International Journal of Women's Health 8, pages 617-626.
Read now
Read now
J. H. Pickar, J. M. Amadio, B. A. Bernick & S. Mirkin. (2016) Pharmacokinetic studies of solubilized estradiol given vaginally in a novel softgel capsule. Climacteric 19:2, pages 181-187.
Read now
Read now
T. Tzur, D. Yohai & A. Y. Weintraub. (2016) The role of local estrogen therapy in the management of pelvic floor disorders. Climacteric 19:2, pages 162-171.
Read now
Read now
A. Pines & D. W. Sturdee. (2015) Personal opinion: Treatment of vulvovaginal atrophy – are hidden interests and misinformation preventing better management?. Climacteric 18:6, pages 802-804.
Read now
Read now
Santiago Palacios & Andrea Mejias. (2015) An update on drugs for the treatment of menopausal symptoms. Expert Opinion on Pharmacotherapy 16:16, pages 2437-2447.
Read now
Read now
C. Bouchard, F. Labrie, D. F. Archer, D. J. Portman, W. Koltun, É. Elfassi, D. A. Grainger, N. Ayotte, T. A. Cooper, M. Martens, A. S. Waldbaum, C. Labrie, I. Côté, L. Lavoie, C. Martel & J. Balser. (2015) Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric 18:4, pages 590-607.
Read now
Read now
R. J. Santen. (2015) Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 18:2, pages 121-134.
Read now
Read now
Sarah H Lindahl. (2014) Reviewing the options for local estrogen treatment of vaginal atrophy. International Journal of Women's Health 6, pages 307-312.
Read now
Read now
Suzanne Reiter. (2013) Barriers to effective treatment of vaginal atrophy with local estrogen therapy. International Journal of General Medicine 6, pages 153-158.
Read now
Read now
J. A. Simon & R. V. Maamari. (2013) Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy. Climacteric 16:sup1, pages 37-43.
Read now
Read now
Lisa A Chism. (2012) Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy. International Journal of Women's Health 4, pages 551-557.
Read now
Read now
Lian Ulrich. (2012) The role of local vaginal estrogen treatment in urogenital atrophy. Expert Review of Obstetrics & Gynecology 7:6, pages 545-556.
Read now
Read now
R. E. Nappi & M. Kokot-Kierepa. (2012) Vaginal Health: Insights, Views & Attitudes (VIVA) – results from an international survey. Climacteric 15:1, pages 36-44.
Read now
Read now
Janet A Chollet. (2011) Efficacy and safety of ultra-low-dose Vagifem (10 mcg). Patient Preference and Adherence 5, pages 571-574.
Read now
Read now
F. Labrie, D. F. Archer, C. Bouchard, M. Fortier, L. Cusan, J.-L. Gomez, G. Girard, M. Baron, N. Ayotte, M. Moreau, R. Dubé, I. Côté, C. Labrie, L. Lavoie, L. Berger, L. Gilbert, C. Martel & J. Balser. (2011) Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 14:2, pages 282-288.
Read now
Read now
D. W. Sturdee & N. Panay. (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13:6, pages 509-522.
Read now
Read now
Articles from other publishers (67)
Ana Carolina M. Comini, Bruno M. Carvalho, Matheus José Barbosa Moreira, Pedro C. Abrahão Reis, Luisa Colapietro, Jane Northern & Felipe Batalini. (2023) Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis. Clinical Breast Cancer 23:8, pages 835-846.
Crossref
Crossref
Frank Z. Stanczyk, Rachel S. Mandelbaum, Harpreet Matharu, Christina E. Dancz & Mark E. Sherman. (2023) Endometrial safety of low-dose vaginal estrogens. Menopause 30:6, pages 650-658.
Crossref
Crossref
Lucia Merlino, Giulia D’Ovidio, Viviana Matys, Maria Grazia Piccioni, Maria Grazia Porpora, Roberto Senatori, Maria Federica Viscardi, Antonio Vitale & Carlo Della Rocca. (2023) Therapeutic Choices for Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors: A Systematic Review and Update. Pharmaceuticals 16:4, pages 550.
Crossref
Crossref
Caroline M. Mitchell, Joseph C. Larson, Carolyn J. Crandall, Shalender Bhasin, Andrea Z. LaCroix, Kristine E. Ensrud, Katherine A. Guthrie & Susan D. Reed. (2022) Association of Vaginal Estradiol Tablet With Serum Estrogen Levels in Women Who Are Postmenopausal. JAMA Network Open 5:11, pages e2241743.
Crossref
Crossref
Abbie J. Laing, Louise Newson & James A. Simon. (2022) Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development. The Cancer Journal 28:3, pages 196-203.
Crossref
Crossref
Daniel María Lubián López. (2022) Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World Journal of Clinical Oncology 13:2, pages 71-100.
Crossref
Crossref
Nèvine te West, Richard Day, Garry Graham, Michael Wright, Christopher White, Gordana Popovic & Kate Hilda Moore. (2020) Serum concentrations of estriol vary widely after application of vaginal oestriol cream. British Journal of Clinical Pharmacology 87:5, pages 2354-2360.
Crossref
Crossref
C. Hocké, M. Diaz, V. Bernard, S. Frantz, M. Lambert, C. Mathieu & M. Grellety-Cherbero. (2021) Syndrome génito-urinaire de la ménopause (SGUM). RPC les femmes ménopausées du CNGOF et du GEMVi. Gynécologie Obstétrique Fertilité & Sénologie 49:5, pages 394-413.
Crossref
Crossref
Suhyun ShimKyung-Min ParkYoun-Jee ChungMee-Ran Kim. (2021) Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements. Journal of Menopausal Medicine 27:1, pages 1.
Crossref
Crossref
. (2020) The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause 27:9, pages 976-992.
Crossref
Crossref
Prasong Tanmahasamut, Titima Jirasawas, Somsak Laiwejpithaya, Chatchai Areeswate, Chongdee Dangrat & Kittayaporn Silprasit. (2020) Effect of estradiol vaginal gel on vaginal atrophy in postmenopausal women: A randomized double‐blind controlled trial. Journal of Obstetrics and Gynaecology Research 46:8, pages 1425-1435.
Crossref
Crossref
Richard J. Santen, JoAnn V. Pinkerton, James H. Liu, Alvin M. Matsumoto, Roger A. Lobo, Susan R. Davis & James A. Simon. (2020) Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. Menopause 27:6, pages 614-624.
Crossref
Crossref
Katie K. Crean-Tate, Stephanie S. Faubion, Holly J. Pederson, Jennifer A. Vencill & Pelin Batur. (2020) Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. American Journal of Obstetrics and Gynecology 222:2, pages 103-113.
Crossref
Crossref
Carolyn J. Crandall, Allison Diamant & Nanette Santoro. (2020) Safety of vaginal estrogens: a systematic review. Menopause 27:3, pages 339-360.
Crossref
Crossref
Richard J. Santen, Sebastian Mirkin, Brian Bernick & Ginger D. Constantine. (2020) Systemic estradiol levels with low-dose vaginal estrogens. Menopause 27:3, pages 361-370.
Crossref
Crossref
Tamara A. Sussman, Megan L. Kruse, Holly L. Thacker & Jame Abraham. (2019) Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy. Journal of Oncology Practice 15:7, pages 363-370.
Crossref
Crossref
Shilpa N. Bhupathiraju, Francine Grodstein, Meir J. Stampfer, Walter C. Willett, Carolyn J. Crandall, Jan L. Shifren & JoAnn E. Manson. (2019) Vaginal estrogen use and chronic disease risk in the Nurses’ Health Study. Menopause 26:6, pages 603-610.
Crossref
Crossref
No Author. (2019) Chapitre 5 : Santé urogénitale. Journal of Obstetrics and Gynaecology Canada 41, pages S73-S81.
Crossref
Crossref
Sheryl A. Kingsberg, Lisa Larkin, Michael Krychman, Sharon J. Parish, Brian Bernick & Sebastian Mirkin. (2019) WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history. Menopause 26:2, pages 124-131.
Crossref
Crossref
Jenifer Sassarini, Mahesh Perera, Keith Spowart, Kay McAllister, Judith Fraser, Ros Glasspool, Rosie Harrand, Marina Chitoni, Sheila Stallard & Mary-Ann Lumsden. (2018) Managing vulvovaginal atrophy after breast cancer. Post Reproductive Health 24:4, pages 163-165.
Crossref
Crossref
Fernand Labrie, David F. Archer, William Koltun, Andrée Vachon, Douglas Young, Louise Frenette, David Portman, Marlene Montesino, Isabelle Côté, Julie Parent, Lyne Lavoie, Adam Beauregard BSc, Céline Martel, Mario Vaillancourt, John Balser & Érick Moyneur. (2018) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 25:11, pages 1339-1353.
Crossref
Crossref
Stephanie S. Faubion, Lisa C. Larkin, Cynthia A. Stuenkel, Gloria A. Bachmann, Lisa A. Chism, Risa Kagan, Andrew M. Kaunitz, Michael L. Krychman, Sharon J. Parish, Ann H. Partridge, JoAnn V. Pinkerton, Tami S. Rowen, Marla Shapiro, James A. Simon, Shari B. Goldfarb & Sheryl A. Kingsberg. (2018) Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. Menopause 25:6, pages 596-608.
Crossref
Crossref
Yuyong Ke, Alain BélangerJean-Nicolas Simard, Renaud Gonthier, Céline Martel, Mario Vaillancourt & Fernand Labrie. (2018) Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy. Menopause 25:3, pages 293-300.
Crossref
Crossref
Carolyn J. Crandall, Kathleen M. Hovey, Christopher A. Andrews, Rowan T. Chlebowski, Marcia L. Stefanick, Dorothy S. Lane, Jan Shifren, Chu ChenAndrew M. Kaunitz, Jane A. Cauley & JoAnn E. Manson. (2018) Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. Menopause 25:1, pages 11-20.
Crossref
Crossref
Fernand Labrie. 2018. Pre-Menopause, Menopause and Beyond. Pre-Menopause, Menopause and Beyond
3
15
.
JoAnn V. Pinkerton, Andrew M. Kaunitz & JoAnn E. Manson. (2017) Vaginal estrogen in the treatment of genitourinary syndrome of menopause and risk of endometrial cancer: an assessment of recent studies provides reassurance. Menopause 24:12, pages 1329-1332.
Crossref
Crossref
Nicoletta Biglia, Valentina Elisabetta Bounous, Marta D'Alonzo, Laura Ottino, Valentina Tuninetti, Elisabetta Robba & Tania Perrone. (2017) Vaginal Atrophy in Breast Cancer Survivors: Attitude and Approaches Among Oncologists. Clinical Breast Cancer 17:8, pages 611-617.
Crossref
Crossref
B. Tamarelle, K. Charvier, L. Badet, J.-E. Terrier, P. Grise, G. Mellier, F. Golfier & A. Ruffion. (2017) Avis d’experts sur les modalités et limites de prescription des estrogènes locaux dans l’incontinence urinaire chez la femme. Progrès en Urologie 27:11, pages 585-593.
Crossref
Crossref
David F. Archer, Ginger D. Constantine, James Simon, Harvey Kushner, Philip Mayer, Brian BernickShelli GrahamSebastian Mirkin. (2017) In Reply:. Menopause 24:8, pages 988-989.
Crossref
Crossref
Alain Bélanger & Wulf Utian. (2017) To the Editor:. Menopause 24:8, pages 988.
Crossref
Crossref
Fernand Labrie, Alain Bélanger, Georges Pelletier, Céline Martel, David F. Archer & Wulf H. Utian. (2017) Science of intracrinology in postmenopausal women. Menopause 24:6, pages 702-712.
Crossref
Crossref
David F. Archer, Ginger D. Constantine, James A. Simon, Harvey Kushner, Philip Mayer, Brian BernickShelli GrahamSebastian Mirkin. (2017) TX-004HR vaginal estradiol has negligible to very low systemic absorption of estradiol. Menopause 24:5, pages 510-516.
Crossref
Crossref
Fernand Labrie & Céline Martel. (2017) A low dose (6.5 mg) of intravaginal DHEA permits a strictly local action while maintaining all serum estrogens or androgens as well as their metabolites within normal values. Hormone Molecular Biology and Clinical Investigation 29:2, pages 39-60.
Crossref
Crossref
Fernand Labrie, David F. Archer, William Koltun, Andrée Vachon, Douglas Young, Louise Frenette, David Portman, Marlene Montesino, Isabelle Côté, Julie Parent, Lyne Lavoie, Adam Beauregard, Céline Martel, Mario Vaillancourt, John Balser & Érick Moyneur. (2016) Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 23:3, pages 243-256.
Crossref
Crossref
Huiyong Wang, Ugo Bussy, Yu-Wen Chung-Davidson & Weiming Li. (2016) Ultra-performance liquid chromatography tandem mass spectrometry for simultaneous determination of natural steroid hormones in sea lamprey ( Petromyzon marinus ) plasma and tissues. Journal of Chromatography B 1009-1010, pages 170-178.
Crossref
Crossref
Yuyong Ke, Renaud Gonthier, Jean-Nicolas Simard, David Archer, Lyne Lavoie, Céline Martel, Mario Vaillancourt & Fernand Labrie. (2015) Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA. Hormone Molecular Biology and Clinical Investigation 24:3, pages 117-129.
Crossref
Crossref
David J. Portman, Fernand Labrie, David F. Archer, Céline Bouchard, Leonello Cusan, Ginette Girard, Normand Ayotte, William Koltun, François Blouin, Douglas Young, Anthony Wade, Céline Martel & Robert Dubé. (2015) Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women. Menopause 22:12, pages 1289-1295.
Crossref
Crossref
Nicoletta Biglia, Valentina E. Bounous, Luca G. Sgro, Marta D'Alonzo, Silvia Pecchio & Rossella E. Nappi. (2015) Genitourinary Syndrome of Menopause in Breast Cancer Survivors: Are We Facing New and Safe Hopes?. Clinical Breast Cancer 15:6, pages 413-420.
Crossref
Crossref
Yuyong Ke, Fernand Labrie, Renaud Gonthier, Jean-Nicolas Simard, Danielle Bergeron, Céline Martel, Mario Vaillancourt, Marlene Montesino, Lyne Lavoie, David F. Archer, John Balser & Erick Moyneur. (2015) Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration. The Journal of Steroid Biochemistry and Molecular Biology 154, pages 186-196.
Crossref
Crossref
Santiago Palacios, Laura Baquedano, Jackie Calleja & Mariela Fernández. (2015) Tratamiento de la atrofia vaginal a través de anillo con liberación de ultrabaja dosis de estradiol. Progresos de Obstetricia y Ginecología 58:8, pages 381-387.
Crossref
Crossref
David F. Archer, Fernand Labrie, Céline Bouchard, David J. Portman, William Koltun, Leonello Cusan, Claude Labrie, Isabelle Côté, Lyne Lavoie, Céline Martel & John Balser. (2015) Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause 22:9, pages 950-963.
Crossref
Crossref
Fernand Labrie, David F. Archer, Céline Bouchard, Ginette Girard, Normand Ayotte, John C. Gallagher, Leonello Cusan, Mira Baron, François Blouin, Arthur S. Waldbaum, William Koltun, David J. Portman, Isabelle Côté, Lyne Lavoie, Adam Beauregard, Claude Labrie, Céline Martel, John Balser & Érick Moyneur. (2015) Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 81:1, pages 46-56.
Crossref
Crossref
Fernand Labrie. (2015) All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause. The Journal of Steroid Biochemistry and Molecular Biology 145, pages 133-138.
Crossref
Crossref
Jonathan Bertin, Johanne Ouellet, Alain Yves Dury, Georges Pelletier & Fernand Labrie. (2014) Expression of the estrogen receptors and steroidogenic enzymes involved in estradiol formation in the monkey vagina. American Journal of Obstetrics and Gynecology 211:5, pages 499.e1-499.e9.
Crossref
Crossref
K. Nathan Parthasarathy & Peter F. Schnatz. 2014. Acute Care and Emergency Gynecology. Acute Care and Emergency Gynecology
37
40
.
. 2014. Acute Care and Emergency Gynecology. Acute Care and Emergency Gynecology
1
158
.
JoAnn E. Manson, Steven R. Goldstein, Risa Kagan, Andrew M. Kaunitz, James H. Liu, JoAnn V. Pinkerton, Robert W. Rebar, Peter F. Schnatz, Jan L. Shifren, Cynthia A. Stuenkel, Margery L.S. Gass & Wulf H. Utian. (2014) Why the product labeling for low-dose vaginal estrogen should be changed. Menopause 21:9, pages 911-916.
Crossref
Crossref
. (2014) RETIRED: Managing Menopause Chapter 5 Urogenital Health. Journal of Obstetrics and Gynaecology Canada 36:9, pages S35-S41.
Crossref
Crossref
David Sturdee. (2014) Urogenital atrophy. Post Reproductive Health 20:2, pages 73-75.
Crossref
Crossref
Rafael Sánchez-Borrego, Montserrat Manubens, Maria Concepción Navarro, Mª Jesús Cancelo, Estanislao Beltrán, Magda Duran, Teresa Orte, Laura Baquedano, Santiago Palacios & Nicolás Mendoza. (2014) Position of the Spanish Menopause Society regarding vaginal health care in postmenopausal women. Maturitas 78:2, pages 146-150.
Crossref
Crossref
Theodora Kunovac Kallak, Juliane Baumgart, Emma Göransson, Kerstin Nilsson, Inger Sundström Poromaa & Anneli Stavreus-Evers. (2014) Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors. Menopause 21:4, pages 383-390.
Crossref
Crossref
Claudine Domoney. (2014) Treatment of Vaginal Atrophy. Women's Health 10:2, pages 191-200.
Crossref
Crossref
Susan WysockiSheryl KingsbergMichael Krychman. (2014) Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clinical Medicine Insights: Reproductive Health 8, pages CMRH.S14498.
Crossref
Crossref
Maja Hellfritzsch Simonsen, Rune Erichsen, Trine Frøslev, Jørgen Rungby & Henrik Toft Sørensen. (2013) Postmenopausal Estrogen Therapy and Risk of Gallstone Disease: A Population-Based Case–Control Study. Drug Safety 36:12, pages 1189-1197.
Crossref
Crossref
Irwin Goldstein, Brian Dicks, Noel N. Kim & Rose Hartzell. (2013) Multidisciplinary Overview of Vaginal Atrophy and Associated Genitourinary Symptoms in Postmenopausal Women. Sexual Medicine 1:2, pages 44-53.
Crossref
Crossref
Fernand Labrie, C?line Martel, Ren? B?rub?Isabelle C?t?Claude Labrie, Leonello Cusan & Jos?-Luis Gomez. (2013) Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. The Journal of Steroid Biochemistry and Molecular Biology 138, pages 359-367.
Crossref
Crossref
. (2013) Management of symptomatic vulvovaginal atrophy. Menopause 20:9, pages 888-902.
Crossref
Crossref
Surveen Ghumman. (2013) Atrophic Vaginitis: Diagnosis and Treatment. Journal of SAFOMS 1:1, pages 4-12.
Crossref
Crossref
Nancy Fugate Woods. (2012) An Overview of Chronic Vaginal Atrophy and Options for Symptom Management. Nursing for Women's Health 16:6, pages 482-494.
Crossref
Crossref
Santiago Palacios, M. Jesús Cancelo, Camil Castelo-Branco, Silvia González & Miguel Ángel Olalla. (2012) Recomendaciones de la Sociedad Española de Ginecología y Obstetricia sobre la prevención y el tratamiento de la atrofia vaginal. Progresos de Obstetricia y Ginecología 55:8, pages 408-415.
Crossref
Crossref
Margaret Rees, Faustino R. Pérez-López, Iuliana Ceasu, Herman Depypere, Tamer Erel, Irene Lambrinoudaki, Karin Schenck-Gustafsson, Tommaso Simoncini, Yvonne T. van der Schouw & Florence Tremollieres. (2012) EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas 73:2, pages 171-174.
Crossref
Crossref
Shannon Wills, Anita Ravipati, Padmaja Venuturumilli, Cynthia Kresge, Elizabeth Folkerd, Mitch Dowsett, Daniel F. Hayes & David A. Decker. (2012) Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Breast Cancer Survivors and Women at Risk of Breast Cancer Taking an Aromatase Inhibitor or a Selective Estrogen Receptor Modulator. Journal of Oncology Practice 8:3, pages 144-148.
Crossref
Crossref
Henrik Griesser, Stefan Skonietzki, Thomas Fischer, Karin Fielder & Marija Suesskind. (2012) Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas 71:4, pages 360-368.
Crossref
Crossref
Nick Panay & Ricardo Maamari. (2012) Treatment of postmenopausal vaginal atrophy with 10-µg estradiol vaginal tablets. Menopause International 18:1, pages 15-19.
Crossref
Crossref
Jeannette M. Potts. 2012. Essential Urology. Essential Urology
259
276
.
James A. Simon. (2011) Identifying and Treating Sexual Dysfunction in Postmenopausal Women: The Role of Estrogen. Journal of Women's Health 20:10, pages 1453-1465.
Crossref
Crossref
Sandhya Pruthi, James A. Simon & Amy P. Early. (2011) Current Overview of the Management of Urogenital Atrophy in Women with Breast Cancer. The Breast Journal 17:4, pages 403-408.
Crossref
Crossref